Tobacco Products and the Risks of SARS-CoV-2 Infection and COVID-19

Nicotine Tob Res. 2020 Dec 15;22(12 Suppl 2):S93-S95. doi: 10.1093/ntr/ntaa187.

Abstract

This commentary addresses the state of the evidence on tobacco products, nicotine, and COVID-19. The evidence of the effects of smoking on respiratory infections and the immune system in general are examined and the current understanding of tobacco products and risk for SARS-CoV-2 infection and the course of COVID-19 is addressed.

Publication types

  • Review

MeSH terms

  • COVID-19 / complications*
  • COVID-19 / epidemiology*
  • Humans
  • SARS-CoV-2*
  • Tobacco Products / adverse effects*
  • Tobacco Smoking / adverse effects*
  • Tobacco Smoking / epidemiology*